us you joining Good today. Thank for evening.
in drugs IND-enabling to today; stage. company transformed in last will clinical-stage Over the has months, of X I its and and drugs pipeline. the Processa a discuss X from a clinical-stage XX one-drug chemistry company toxicology are we've drugs, X the are that which
the clinical pipeline. August gastroparesis. drugs targeting In month of targeting The patients; groups options. named are Both better the which XXXX, XXXXX, cancer our patients of up alone, and X X make treatment seek patients drugs we with of in-licensed
$X well lipoidica of $X short. greater goal, indications million. billion ulcerative as our has we which a uplisted with than we have NASDAQ NL more NL $X months, Each treat a these raised have to total over for market, billion our market, market, the market. to a means That addressable Ulcerative or X ulcerative tripled potential $XX.X on we and billion each XXX, also drug last necrobiosis as addressable complements addressable or XX shots total
In to then order ] we briefly what [ -- pipeline. next? and to me do, how approach, we quickly clinical which planning our expect describe we what is from review other companies, expect understand So are biotech our different let
model. can it briefly you from slide, business As see summarizes Processa's this
Chief applies Sian is based our Officer, and have our a last in approach develop Processa on FDA the The to experience and guidances decisions science Development XXX regulatory over years. approach that we FDA which XX our teaching XX and regulatory working Bigora, First, developed in FDA reviewers, and on over contracts X with approvals something involvement support FDA studies FDA meetings. we over conducted I
Second, a capital-efficient are we company.
markets in after over approvals expected months. our clinical capital ready our have X given who with XX all to development have of we're part separate Directors a of pipeline. obtaining history this, of team move specific value. raise, next to to management be X creating milestones a team, XX drugs our defined for we the FDA a criteria of Fourth, uplist forward key Third, Board on X finally, And and drugs, with have a and and trials we clinical-stage
not treat off, we're have drug drug must company? a So drug what our high and need is who drug pipeline medical criteria discovery condition. given First unmet development the patients company a a
a the efficacy development there process, drug population of similar be target and to evidence patients. with our of success pharmacology in or derisk Second, the in improve of order drug the must probability for
drug probability our indicate success see of drug our to to And capital-efficient is that of approval. to on on investment, Third, cash, the finally, and which spend, Fourth, increasing a to time potential approach evaluation return would must drugs the the related in and science return potentially able only the approval, we approach we of high the with want market potential be the a competition. developing success, must be regulatory investment. to useful probability
what discusses X, with of we X happens criteria companies. One stage our reason whole strict This X. that biotech next gamut slide do and the is pipeline for typically don't
and is Our approach X. stage focused in X on
what increasing requires design to clinical a note in know we so are FDA's development as program through in in each drug X, FDA to move best approach future therefore, anticipate a is More specific indication, to that itself. that in as Processa probability approve reviewers the to a discussions. able important well FDA importantly, information of approval stage drug we It the as we're to the and we drug way of study value increasing and, help studies of each should the provide the our
the criteria lists This left. pipeline our on slide briefly
when orange, different each and blue clinical to drugs our of the companies drugs. identifying dollars On X millions numbers. studies The possible develop right have green top be these X pipeline. completing more are using of hundreds just these are them for studies in their Processa on I'll Prior efficiently drugs spent will in our by drug. be drugs. pipeline the X
further We for X our their safety. to these studies expect efficacy clinical planned drugs clinically and validate
such how dehydrogenase, the and metabolites briefly X-FU which the themselves forms happens dihydropyrimidine the XXXX have What that and the is nor first represented inhibits The Xeloda years. X-FU. metabolized orally X-FU or DPD. by metabolites green and Neither Xeloda kill enzyme These an kill is XX% are cancer been clinical-stage discuss me the that approximately as than called cancer work. arrow cancer drug chemotherapy to more administered describe understand These is the cells. X how cells. cornerstones let on to of left. box of X-FU that XXXX, the is for In order cells Xeloda I'll XX drugs works,
the side that side DPD. such hand-foot that not enough the red stop patients right, significant ideal syndrome the XX% to chemotherapy. dose, are have can for the the effects These cancer the when HFS. cause or at by metabolites metabolized is effects, taking formed look enzyme you reduce be as X-FU other the symbolizes If These cancer can or of metabolites drug
novo the What DPD This the those And irreversibly is the associated none XXXX as it de pushed inhibited. then to and DPD again back the are Xeloda formed tumor left, with in cell-killing inhibits is metabolite after does is we the DPD metabolites such metabolite. metabolism new right do enzyme DPD metabolite XXX% so increasing right body side again the blocked, the of forming are long are the mainly instead, activity the to as X-FU enzymes -- synthesized to then and are antitumor X-FU. effects the Only the eliminates metabolites the come and formed. that see and effect is of
patients breast So X-FU the Xeloda? colorectal combination first-line as load the and of In cancer. as U.S., population what XXXX such thousands Xeloda of in is target cancers receive our for cancer hundreds cancer, of and chemotherapy
was patients billion. a to the In side receiving market peak as To for XXXX you XXXX, X-FU HFS. potential effects of in develop Xeloda such XX% the Xeloda of XX% addition, and $X.X sense the give sales approximately
side Or patients of had have that combined a the circle XXXX could we side of survival the who severity survival maybe or believe Wouldn't even as effects. and it we a Xeloda effects be can decreases on which -- and we time, progression-free the if achieve shown Well, the right? both. drug that percent maybe great increases with increase have blue oblong we in drug
to given efficacy worked Xeloda XXXX on in improving safety easy XXXX with Xeloda. significant oncology pipeline personally the past, expanding may the combined Xeloda on was have development the adding an decision in our X-FU and impact Having and of that and our
excited additional reasons why should are XXXX emphasize. so we're also I that about There
exposures we dosage XXXX optimize determine the human and increase decrease XXXX and Xeloda. we We've the had finally cancer X,XXX side believe effects. dosage that able optimize in to and regimen First, how that regimen to efficacy out patients. But in figured been has can I
DPD just a same -- with platform could it's drugs other is chemotherapy used that XXXX Second, Xeloda. anticancer be are major the Therefore, other that There enzyme. with issue with not the drugs. had DPD
the Xeloda we decrease This describe efficacy. side slides right side could saw shows decreases the XXXX effects next side effects The briefly on of the XXXX our type of slide diagram. X improve how HFS metabolism and giving the how that
red side different Xeloda X-FU. given is XXXX see effects side is X-FU, can are the with HFS given XXXX give X-FU they effects with effects Circle the is when where You circle And X-FU. from when The Blue nonexistent side by Xeloda and the the almost encompasses HFS itself. or than
have the resistant line on at looking XFU, going straight slide, these survival like days. XXX the XX up were XXX to first In and looks during began the their days down, Xeloda, staircase, plot XXXX that of cancer up to and switched When XXX patients with as progression-free seen this in were progressed -- survival patients a to progression-free patients to days the some patients median and to a drug.
So the regimen be the from and maximum clearance step? do will the what have tolerated of Ib And IND Phase side upcoming the to that are the evaluate Xeloda dose the effects safe efficacy. what of milestones? is the trial. will look on a next high can FDA Xeloda determine dosage a It XXXX The We at administered. trial dose to oncology already received
Phase We quarter in or expect expect of 'XX. 'XX, the results half or dosing and the XXXX. of announce we and to first first second to our interim quarter plan in Ib second in third to We fourth of the sites patient initiate trial end the begin
next now Let's the look drug, XXX.
as As on the an the there drug an slide, forms human analog of in this is different are an you'll body; the metabolites called pentoxifylline. XXX pentoxifylline of active metabolite Qualitatively, amounts of it but metabolites. approved quantitatively, see same
these metabolites its slightly the the light the and boxes and differing XXX metabolites its pharmacological body the light blue boxes on different -- its properties, as metabolites. than results in in XXX to amounts in seen and a responding the metabolites Since right, blue have variety pentoxifylline of of
drug has to fact, more side pentoxifylline. XX% effects than than In XXX pentoxifylline, us less allowing patients to give
and could diverse Given being might given we patients. advantage NL in in the able be patients. be that an the an indication NL, to XXX found of orphan to at used doses pentoxifylline higher XXX pharmacology called And diverse these of looked pharmacology is these be
are This the slide boxes represents what actually its pharmacological and metabolites. at bottom the of properties XXX
the represent the If in X the you that boxes, look NL. at occur top the pathophysiological boxes top changes at
arrows, changes. red typically of see in the of at the the at would targets while X out pharmacological time, what the at you of X look red all XXX that is of of you X X Right arrows changes X XXX affect occur And the pathophysiological that If where properties the physicians affect can NL. tell actually changes treat pharmacological the you now, a one pathophysiological NL pathophysiological time. treat XXX
becomes what of approximately NL? skin XX% the of is forming In treatment ulcers There skin below open NL. is necrotic the So in NL and patients, the any or cure for tissue form with no FDA-approved patients.
market. of XXXX, ulcerated is the NL. XX,XXX There So this potential U.S. just are to approximately form $X patients like XX,XXX in the a billion with
is it slide, on you not but black all below on at see look tissue the also in necrotic surface, the actually the necrotic can the just tissue shin. on you If left picture the It right necrotic of be the side the surface. the
estimate natural than in patients cannot first to we doses patients dose actually and do dose and after the ulcers the need reason patients onset X evidence There closure. often of of the the and not these take some pentoxifylline and less respond that of years tolerate much dose, some X can tolerate who is closing years. that the the with highest for that may patients, years ulcers during complete patients than pentoxifylline is can XX% Unfortunately, years highest have higher a more the maximum allowed. pentoxifylline The incurs patients
highest a XX% dose than the pentoxifylline patients our completely study, X which patients. And tolerated while was of greater they patient XXX were on well was the who ulcers NL all first of in the in had our In ulcers, closed dose XXX.
there talked Well, with FDA, we approval. what disease the III other agreed and we a have this given if we and Now FDA treatments, Phase the are we negotiated trial, no positive going could forward? is single given doing that we with get then has potentially them,
the approval. trial to data dosing starting designed results to first first us the Given getting help and we've interim IIb key upcoming trial design value-adding second The a increase which approval, half into increase positive, Phase half obtaining in Processa. the XXXX, interim are that, XXXX, XXXX; XXXX. of just after in probability probably in our study of completion is out increase the a of it of single in 'XX; Phase we will of Like XXX results study give the milestones if report the an significantly of us the of patient translate and value III probability FDA next would
in XXXXX. third Moving receptor X-HTX to clinical pipeline, final look highly selective and drug a agonist. let's the is and XXXXX potent our at novel,
treat conditions. X-HTX XXXXX in be to than selective such disorders, the drugs, shown As which -- various as and table, is potent shown gastroparesis be more been and other treat to motility successfully top able constipation GI have
and side selective to effects either market X-HTX have In from addition, or are XXXXX, not -- has bottom which other X-HTX drugs, as less less seen cardiovascular removed table, the compared approved. than in the to been
target significantly that first condition will nausea, that affect of GI such market symptoms we emptying as result $X medical is XXXXX unmet the long population food is there tract So quality have problems moving stomach is a life. symptoms the billion for is such The and many be significant an can population? need Our targeting the eating. and that has where the other gastric down bloating delay condition gastroparesis. of abnormally vomiting, patient's what's in our after Gastroparesis patients
antagonists, is patients are or dopamine major treatment X,XXX only to and are which drugs been X agonists, X-HTX with receptor of gastroparesis, FDA-approved significantly X shown They the metoclopramide. which cisapride; have gastroparesis. are for There help types which like
associated as drug types table other see side could so bottom, side the you the pulled than them receptors cardiovascular the As cisapride and the drugs, effects the effects example, to the from less-specific But drugs at X-HTX. such X-HTX can cisapride, efficacious. the be given metoclopramide of off that, the for significant are significant, was market with binding with associated
faster the describes with -- top first bottom had vehicle, evidence a to emptying the So happened study work vehicle. XXXXX. will circle that, The or was red what's piece rate XXXXX a XXXXX gastroparesis? that evidence Our what the gastric where monkey when represents had and they the placebo where in line what of placebo or compared represents happens
the was see, can rate emptying you As the faster much bottom. for
a is the the at the green slide This little rate baseline. The in for which on the XXXXX, and was top; gastric given, circles black different This drug a is faster are constipation slide. being represent so patients. no circles bottom emptying
can see, As are higher. actually the you top
the actual actually So rate. represents this actually --
drug. than faster the the was rate So no just of baseline
in So are forward? expect early with moving do to to going meet gastroparesis intend second and the half first what 'XX. in a we in initiate program, of to 'XX. Phase interim we half the 'XX be second is an trial the do We sometime to II define further development half of completion we the in the expected with The do? What 'XX, Phase to trial in IIa of clinical analysis FDA expected
put and I've deliverables drugs for our clinical the all time next summary, through pipeline. in XXXX the line months XX over to of together and In XX the
the increase to and XXXX this XXXX, which positive FDA final results results to hopefully we with interim probability in time, value During and potentially in of the will expect increase Processa. approval obtain
we team, approvals Floyd as division before to to which Directors. we Khalid significant Both fortunate Michael individuals like and also Operation to for and brought Directors us. created former value to team have development every open success almost successfully our of Board the of their these shareholders an are FDA, that add fortunate in with has companies, critical expect we for management been of have Islam with obtained and the previous So were together we of recently, would have FDA less the and no company's mention up the Q&A, that experienced I companies. Officer; add Board to Chief in Most
will first XX closing, as opportunity of the In starting the XXXX, milestones including achieving 'XX the about XXXXX, trials well key be shareholder XX over and we near-term excited as results increasing months, to X the we of are given half for XXX next interim value.
remarks. lines ask the to my please you will open poll now Thank concludes phone I can questions? you. the for for Operator, Q&A. operator That
